DRL gears up for biosimilar push, consumer health growth post record FY25
Dr Reddy’s stock rose 5.5% in six sessions post-Q4 results, outperforming the BSE Healthcare index. Strong revenue growth, biosimilar launches, and semaglutide portfolio support long-term prospects despite Revlimid taper and reduced target prices by (...)
Site référencé: The Economic Times
The Economic Times
Ant Financial to sell shares worth Rs 2,200 crore in Paytm parent
13/05/2025
Pharma stocks decline amid Trump’s prescription drug price cuts announcement
13/05/2025
Metal stocks surge as US-China trade deal eases economic concerns
13/05/2025
Indian market soars nearly 4% as geopolitical tensions ease
13/05/2025
Fusion Finance's Rs 800-crore rights issue fully subscribed
12/05/2025
Bharti Airtel Q4 Preview : PAT may jump up to 226% YoY on robust ARPU. Up to 35% revenue uptick seen
12/05/2025
